Move over, amyloid, reactive astrocytes and activated microglia may be the main drivers of the Alzheimer’s disease pathological cascade. In the November 6 Nature Neuroscience, scientists led by Pedro ...

Hypertension heightens the risk of Alzheimer’s disease, but exactly how is not understood. In a bioRxiv preprint posted September 19, scientists led by Costantino Iadecola at Weill Cornell Medical ...

Antisense oligonucleotides have emerged as a promising approach for treating neurodegenerative disease. They can dial down toxic proteins or help restore functional ones, and have been approved for ...

Back in mid-June, Alzforum reported on how the AD research field was being buffeted by cuts in funding to the National Institutes of Health (Jun 2025 news; Jun 2025 news). At the time, scientists felt ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Austria’s beautiful capital city of Vienna hosted the 19th International Conference on Alzheimer’s and Parkinson’s diseases, which drew a record 5,554 attendees from 76 countries. From April 1 to 5, ...

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U.S. marketing approval. What ...